
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio Ltd has shown a significant upward movement in stock price during the third quarter, propelled by a competitor's failure to meet key study endpoints, indicating potential market share opportunities. The company is actively advancing its clinical-stage assets, with $42.1 million allocated to research and development this year, reflecting a commitment to validating the efficacy and safety of its pipeline therapies. Additionally, the upcoming increase in diagnoses of autoimmune and inflammatory diseases supports a promising market landscape, which could enhance the demand for Zura Bio's innovative treatment solutions.
Bears say
Zura Bio faces significant challenges with its asset efficacy profiles, as current trials indicate that its candidates, particularly in comparison to established treatments, may demonstrate weaker performance in key therapeutic areas. The historical underperformance of similar treatments, such as Cosentyx, further exacerbates concerns around market acceptance and potential revenue generation due to poor market uptake linked to safety warnings. Additionally, while general and administrative expenses have decreased, this reduction may not sufficiently mitigate the financial risks associated with the company's development pipeline and the doubtful efficacy of its leading assets.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares